


The background of the slide features a microscopic view of biological structures. In the upper left, there is a large, complex, purple-colored mass with a textured, almost crystalline appearance. The rest of the background is filled with numerous smaller, elongated, Y-shaped or branching structures in shades of red and blue, which appear to be out of focus compared to the purple mass.

Nivolumab Improves Objective Response Rate in Advanced Renal Cell Carcinoma


CheckMate 025 Japanese subgroup analysis

Ellen Grünewald, August 31st, 2020

Advanced renal cell carcinoma (aRCC)



Annually 338,000 new cases of RCC diagnosed worldwide



Approx 30% of patients present with metastatic disease at diagnosis




Standard treatment for aRCC is everolimus, an mTOR inhibitor




Nivolumab, a PD-1 immune checkpoint inhibitor, is now approved for aRCC

Does nivolumab increase survival compared to everolimus in advanced renal cell carcinoma?




Does nivolumab increase survival compared to everolimus in advanced renal cell carcinoma?




Does nivolumab increase survival in Asian/Japanese patients?

Does nivolumab increase survival in Asian/Japanese patients?




Does nivolumab increase survival in Asian/Japanese patients?




Nivolumab improved OS in global population

In Japanese population median not reached




Nivolumab improved OS in global population


In Japanese population median not reached




Higher ORR with nivolumab in Japanese consistent with global population




Does nivolumab increase survival in Asian/Japanese patients?



Does nivolumab increase survival in Asian/Japanese patients?



A microscopic image showing a large, textured purple cell in the upper left corner. The background is filled with numerous smaller, elongated cells, some colored red and others blue, scattered across the field of view.

This study supports the use of nivolumab in advanced renal cell carcinoma and highlights the importance of including Asian populations in global studies